BioAgilityx announces bolt-on acquisition

04 November 2019

---

BioAgilityx announces bolt-on acquisition.

4 November 2019

BioAgilytix, a leading provider of large molecule bioanalytical testing services, today announced that it has acquired Cambridge Biomedical, a contract research organization based in the Cambridge area of Massachusetts, which also specializes in large molecule bioanalysis.

The transaction expands BioAgilytix’s global footprint into the heart of the world’s major biotech center, and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany. It also grows BioAgilytix’s premier team to more than 400 employees worldwide, bringing on board Cambridge Biomedical’s seasoned bioanalytical scientists to complement and further enhance BioAgilytix’s world-class expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development.

Cambridge Biomedical has particularly extensive capabilities in kit production as well as a premier molecular suite equipped with the latest generation of PCR platforms, both of which will be immediately available to BioAgilytix’s customers.